eFFECTOR Therapeutics Collaborates With Stanford Medicine Mid-Stage Breast Cancer Study

eFFECTOR Therapeutics Inc EFTR will collaborate with Stanford Medicine on an investigator-initiated randomized Phase 2 study evaluating zotatifin in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a preoperative setting.
Zotatifin will be tested in specific genomically-defined subgroups, including standard-risk patients and high-risk patients carrying specific markers predictive of relapse.
In all three cohorts, patients will be randomized to receive a single dose of zotatifin plus fulvestrant, or fulvestrant alone, 14 days before surgery.
The study's primary objective is to assess change in tumor proliferative status, measured by Ki67 staining, from baseline to 14 days after preoperative treatment with either regimen.
This clinical trial will investigate how zotatifin might affect tumor growth, compared to standard of care, in patients with these specific high-risk genomic profiles, as well as in patients with standard risk. The goal is to develop precision approaches to improve breast cancer outcomes."
In February, the company announced topline data from zotatifin study in COVID-19 patients. The data demonstrated favorable safety results and positive trends in several measures of antiviral activity.
Price Action: EFTR shares closed at $0.35 on Monday.